Molecular Cancer Therapeutics Impact Factor, Quartile, Indexing, Ranking

Molecular Cancer Therapeutics (MCr) is a scholarly journal dedicated to publishing research in the field of Medicine, and Published by American Association for Cancer Research. The Print-ISSN of Molecular Cancer Therapeutics is 1535-7163 and its abbreviation is Mol Cancer Ther.

The Publicaiton fees (APC) is Base Fee, $1900, OA Price $6000.

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.

Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.

The following guidelines, which may be revised from time to time, describe what the Editors are looking for in submitted manuscripts:

• Data/experiments are substantive and support conclusions; all key experiments are designed and performed properly.
• Sufficient detail is provided to facilitate repetition of the experiments to verify data.
• Rigorous statistical evaluation is performed. Sufficient group size is used for animal studies.
• Appropriate replicates in cellular studies are used.
• Relevant cell lines, animal models, and assays are utilized.
• Studies must be performed according to AACR and Institutional Guidelines.
• Multiple relevant cell lines (or patient specimens) are examined/used/studied to support conclusions.
• Studies are performed using relevant concentrations of agents, conditions, schedules, and other related material. Where human data exists, the data should be used to define parameters for laboratory studies.
• Appropriate controls are employed for all experiments (especially inactive analog compounds).
• In vivo studies should go beyond establishment of biological effect and show modulation of the intended target (or cellular pathway) in vivo. Pharmacokinetic (PK)/pharmacodynamics (PD) studies are extremely useful; dose-response should be demonstrated.
• Inclusion of relevant structures of compounds mentioned or used in the work is essential and enhances the readability of the paper. Studies with uncharacterized mixture of Natural Products will not be considered.
• For novel structures previously unreported, experimental details of synthesis should be included in the main body of the paper or in Supplementary Material.
• Any references or patents cited that provide the synthesis of compounds should be specific, not general, and should be easily obtained.

• Journal Website
• PubMed
• Scopus
• SCImago